Sclerostin serum levels correlate positively with bone mineral density and microarchitecture in haemodialysis patients
- 25 May 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 27 (1), 226-230
- https://doi.org/10.1093/ndt/gfr270
Abstract
Sclerostin is a soluble inhibitor of osteoblast function. Sclerostin is downregulated by the parathyroid hormone (PTH). Here, it was investigated whether sclerostin levels are influenced by intact (i) PTH and whether sclerostin is associated with bone turnover, microarchitecture and mass in dialysis patients. Seventy-six haemodialysis patients and 45 healthy controls were included in this cross-sectional study. Sclerostin, Dickkopf-1 (DKK-1), intact parathyroid hormone (iPTH), vitamin D and markers of bone turnover were analysed. A subset of 37 dialysis patients had measurements of bone mineral density (BMD) using dual-energy X-ray absorptiometry and bone microarchitecture using high-resolution peripheral quantitative computed tomography. Dialysis patients had significantly higher sclerostin levels than controls (1257 pg/mL versus 415 pg/mL, P < 0.001). Significant correlations were found between sclerostin and gender (R = 0.41), iPTH (R = -0.28), 25-hydroxy-cholecalciferol (R = 0.27) and calcium (R = 0.25). Gender and iPTH remained significantly associated with sclerostin in a multivariate analysis. Sclerostin serum levels were positively associated with BMD at the lumbar spine (R = 0.46), femoral neck (R = 0.36) and distal radius (R = 0.42) and correlated positively mainly with trabecular structures such as trabecular density and number at the radius and tibia in dialysis patients. DKK-1 was related neither to bone measures nor to serologic parameters. Considering that sclerostin is an inhibitor of bone formation, the observed positive correlations of serum sclerostin with BMD and bone volume were unexpected. Whether its increase in dialysis patients has direct pathogenetic relevance or is only a secondary phenomenon remains to be seen.Keywords
This publication has 28 references indexed in Scilit:
- Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibodyJournal of Bone and Mineral Research, 2010
- Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strengthJournal of Bone and Mineral Research, 2010
- Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal WomenJournal of Clinical Endocrinology & Metabolism, 2010
- Control of Bone Mass and Remodeling by PTH Receptor Signaling in OsteocytesPLOS ONE, 2008
- Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation and Bone StrengthJournal of Bone and Mineral Research, 2008
- Regulation of bone mass by Wnt signalingJCI Insight, 2006
- Chronic Elevation of Parathyroid Hormone in Mice Reduces Expression of Sclerostin by Osteocytes: A Novel Mechanism for Hormonal Control of OsteoblastogenesisEndocrinology, 2005
- Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem diseaseJournal of Medical Genetics, 2002
- Dickkopf1 Is Required for Embryonic Head Induction and Limb Morphogenesis in the MouseDevelopmental Cell, 2001
- Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing ProteinAmerican Journal of Human Genetics, 2001